Connect Biopharma Holdings Ltd (CNTB) research
Connect Biopharma Holdings Ltd- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.93
- As of
Connect Biopharma Holdings Ltd (CNTB): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-30.
As of . Source: SEC EDGAR filings for CNTB. Method and limitations.
Share the CNTB intelligence card
See the full CNTB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CNTB on one page. Preview it with sample data, then open it live with a free account.
Preview the CNTB dossierActive signals for CNTB
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 16.0%, EPS $-0.27 vs $-0.3213 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 91% of CNTB (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +320% to CNTB (2026Q2)
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 29.8% - EPS $-0.27007 vs $-0.208 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 50.2% - EPS $-0.33998 vs $-0.2264 estimate
FREE, NO ACCOUNT
Every signal on CNTB, as it fires
You are seeing 5 of 10 signals recorded on CNTB since 2026-05-29.
The five above landed across 3 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CNTB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP G23549101 · 2026Q2 | $475K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP G23549101 · 2026Q2 | $208K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G23549101 · 2026Q2 | $104K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CNTB
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CNTB against its peers
CNTB's operating margin of -90740.6% ranks in the 6th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | CNTB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 64000 USD | 3.3M USD | 29 | 11 |
| Operating margin | -90740.6% | -93.5% | 6 | 8 |
| Net margin | -86687.5% | -44.4% | 6 | 8 |
| Return on equity | -132.2% | -76.5% | 36 | 17 |
Peers (21): KLRS, CSBR, SPRO, HRTX, RNXT, ALDX, CING, GOSS, XBIT, GUTS, MAIA, FBIO, PMVP, ATHE, TENX, RNTX, INKT, HYPD, AURX, OSTX, GANX. Left out: APLM (period gap), OKYO (period gap), BSEM (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (CNTB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CNTB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CNTBand get the insider, 13F, options, and confluence read in one view.